Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. (Q38121422)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Noreen Latief

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Shah Jahan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

13 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

Archives of Virology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1-15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis C virus biology

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Evolving epidemiology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Nomenclature and numbering of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Current therapy for hepatitis C: pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus genotype 4 therapy: progress and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

PKR--a protein kinase regulated by double-stranded RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

The interferon antiviral response: from viral invasion to evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Interferon-based therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Are all type I human interferons equivalent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

The human interferon alpha/beta receptor: characterization and molecular cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Interferon signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Interferons: mechanisms of action and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

A reinterpretation of the dimerization interface of the N-terminal domains of STATs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Identification of a nuclear Stat1 protein tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

JAK/STAT signaling by cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Repression of Interferon Regulatory Factor 1 by Hepatitis C Virus Core Protein Results in Inhibition of Antiviral and Immunomodulatory Genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence and structure-based prediction of eukaryotic protein phosphorylation sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Positional effect of phosphorylation sites 266 and 267 in the cytoplasmic domain of the E2 protein of hepatitis C virus 3a genotype: interferon resistance analysis via sequence alignment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

E2 of hepatitis C virus inhibits apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Evolution of the hypervariable region of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Constrained genomic and conformational variability of the hypervariable region 1 of hepatitis C virus in chronically infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

HCV genetic elements determining the early response to peginterferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Viral strategies of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus: the role of molecular mimicry in response to interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Unscrambling hepatitis C virus-host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-013-1780-X

10.1007/S00705-013-1780-X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 March 2020

1000922990

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23851652%20AND%20SRC:MED&resulttype=core&format=json